ArticlePloS one2025
Cancer related adverse events associated with use of proton pump inhibitors and histamine-2 receptor antagonists: A real-world analysis using the FDA adverse event reporting system.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Drug spectrum and disproportionality signals for diabetes insipidus in FAERS: multi-method analysis, JADER cross-database assessment, and PubMed-based case-level evidence.Frontiers in pharmacology · 2026Article
- Reported drug spectrum and disproportionality signals for malignant neoplasm progression in FAERS: a real-world pharmacovigilance study.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite widespread use, concerns have emerged regarding the increased risks of digestive system cancers associated with use of proton pump inhibitors (PPIs). Moreover, ranitidine was recalled from the market in some countries due to its potential carcinogenicity, which also has raised concern about cancer risk in association with use of histamine-2 receptor antagonists (H2RAs). We comprehensively explored the potential risks of various cancers associated with use of PPIs and H2RAs by analyzing the FDA Adverse Event Reporting System (FAERS), aiming to offer real-world evidence for the safe and rational use of acid suppressive agents. OpenVigil 2.1 was utilized to query the FAERS database. Cancer related adverse events (AEs) included Preferred Terms (PTs) of malignant neoplasms among all cancer sites. Disproportionality analysis was performed, and a positive signal indicated a statistical association between cancer related AEs and drugs. Most PPIs had more cancer related PTs with positive signals than H2RAs (except ranitidine), but had fewer cancer related PTs with positive signals than ranitidine. Forty-three cancer related PTs exhibited positive signals for more than one PPIs, and the major cancer sites of these PTs were gastric, lung, lymphomas, pancreatic, oesophageal, intestinal, upper respiratory tract, renal, soft tissue, and so on. Besides, only two cancer related PTs exhibited positive signals for more than one H2RAs (except ranitidine). Our study suggests that PPIs may be associated with more cancer related AEs than H2RAs (except ranitidine), but may be associated with fewer cancer related AEs than ranitidine. Except for digestive system cancers, use of PPIs may also be associated with increased risks of multiple non-digestive system cancers. According to our findings, H2RAs (except ranitidine) may be safer than PPIs regarding cancer risk, and the priority use of PPIs for acid suppression therapy may not be appropriate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.